● First Tracks Biotherapeutics shares have fallen sharply, most recently closing at $41.90, down 7.91%, cooling after a rally driven largely by a single-day jump tied to a competitor's positive CD122 data.
● REGENXBIO shares have fallen sharply, most recently closing at $11.06, down 7.99%, two weeks after reporting Q2 2026 results.
● RH shares have fallen sharply, most recently closing at $156.41, down 7.98%, alongside a broad retail selloff triggered by Walmart's report showing U.S. comparable sales growth of about 2.6%, versus roughly 3.8% expected.
● TransCode Therapeutics shares have fallen, most recently closing at $2.97, down 7.48%, carrying a marketCapitalizationof roughly $3.6 million with only about 1.1 million shares outstanding following a 1-for-28 reverse stock split.
● Regentis Biomaterials shares have fallen, most recently closing at $2.06, down 7.62%, with a marketCapitalizationof roughly $10 million.
● PROG Holdings shares have fallen, most recently closing at $38.20, down 7.62%, despite Q2 2026Revenueof about $719.7 million, up 19% year over year, and adjusted EPS of roughly $1.19 beating consensus.
● Prime Medicine shares have fallen sharply, most recently closing at $3.24, down 8.47%, amid a broad selloff in speculative biotech as long-term Treasury yields rose to their highest level in nearly two decades.
● NextCure shares have fallen sharply, most recently closing at $6.25, down 7.82%, as the market continues repricing the stock around its pendingReverse mergerwith Avere Therapeutics.
● Odysight.ai shares fell sharply after the company priced a public offering of 3,437,500 shares at $3.20 each for roughly $11 million in gross proceeds.
● OptimumBank Holdings shares have fallen sharply, most recently closing at $9.22, down 8.71%, despite having roughly doubled over the trailing twelve months.